🎉 M&A multiples are live!
Check it out!

INmune Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for INmune Bio and similar public comparables like Pharming, Julphar, and Galapagos.

INmune Bio Overview

About INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.


Founded

2015

HQ

United States of America
Employees

22

Website

inmunebio.com

Financials

LTM Revenue $10K

LTM EBITDA n/a

EV

$153M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

INmune Bio Financials

INmune Bio has a last 12-month revenue of $10K and a last 12-month EBITDA of n/a.

In the most recent fiscal year, INmune Bio achieved revenue of $14K and an EBITDA of -$42.6M.

INmune Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See INmune Bio valuation multiples based on analyst estimates

INmune Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.2M $14K XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$29.7M -$42.6M XXX XXX XXX
EBITDA Margin -19188% -304536% XXX XXX XXX
Net Profit -$27.3M -$30.0M XXX XXX XXX
Net Margin -17612% -214343% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

INmune Bio Stock Performance

As of April 15, 2025, INmune Bio's stock price is $8.

INmune Bio has current market cap of $173M, and EV of $153M.

See INmune Bio trading valuation data

INmune Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$153M $173M XXX XXX XXX XXX $-2.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

INmune Bio Valuation Multiples

As of April 15, 2025, INmune Bio has market cap of $173M and EV of $153M.

INmune Bio's trades at 15323.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate INmune Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for INmune Bio and 10K+ public comps

INmune Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $153M XXX XXX XXX
EV/Revenue 10915.4x XXX XXX XXX
EV/EBITDA -3.6x XXX XXX XXX
P/E -4.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get INmune Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

INmune Bio Valuation Multiples

INmune Bio's NTM/LTM revenue growth is 15504%

INmune Bio's revenue per employee for the last fiscal year averaged $1K, while opex per employee averaged $1.9M for the same period.

Over next 12 months, INmune Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate INmune Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for INmune Bio and other 10K+ public comps

INmune Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -91% XXX XXX XXX XXX
EBITDA Margin -304536% XXX XXX XXX XXX
EBITDA Growth 43% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -289031% XXX XXX XXX XXX
Revenue per Employee $1K XXX XXX XXX XXX
Opex per Employee $1.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 67736% XXX XXX XXX XXX
R&D Expenses to Revenue 236900% XXX XXX XXX XXX
Opex to Revenue 304636% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

INmune Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

INmune Bio M&A and Investment Activity

INmune Bio acquired  XXX companies to date.

Last acquisition by INmune Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . INmune Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by INmune Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About INmune Bio

When was INmune Bio founded? INmune Bio was founded in 2015.
Where is INmune Bio headquartered? INmune Bio is headquartered in United States of America.
How many employees does INmune Bio have? As of today, INmune Bio has 22 employees.
Who is the CEO of INmune Bio? INmune Bio's CEO is Dr. Raymond J. Tesi, M.D..
Is INmune Bio publicy listed? Yes, INmune Bio is a public company listed on NAS.
What is the stock symbol of INmune Bio? INmune Bio trades under INMB ticker.
When did INmune Bio go public? INmune Bio went public in 2019.
Who are competitors of INmune Bio? Similar companies to INmune Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of INmune Bio? INmune Bio's current market cap is $173M
What is the current revenue of INmune Bio? INmune Bio's last 12-month revenue is $10K.
What is the current EV/Revenue multiple of INmune Bio? Current revenue multiple of INmune Bio is 15323.5x.
What is the current revenue growth of INmune Bio? INmune Bio revenue growth between 2023 and 2024 was -91%.
Is INmune Bio profitable? Yes, INmune Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.